Method for administering insulin to the buccal region
A mixed micellar pharmaceutical formulation includes a micellar proteinic pharmaceutical agent, an alkali metal C8 to C22 alkyl sulfate, alkali metal salicylate, a pharmaceutically acceptable edetate and at least one absorption enhancing compounds. The absorption enhancing compounds are selected from the group consisting of lecithin, hyaluronic acid, pharmaceutically acceptable salts of hyaluronic acid, octylphenoxypolyethoxyethanol, glycolic acid, lactic acid, chamomile extract, cucumber extract, oleic acid, linolenic acid, borage oil, evening primrose oil, trihydroxy oxo cholanylglycine, glycerin, polyglycerin, lysine, polylysine, triolein and mixtures thereof. Each absorption enhancing compound is present in a concentration of from 1 to 10 wt./wt. % of the total formulation, and the total concentration of absorption enhancing compounds are less than 50 wt./wt. % of the formulation. Methods for administering insulin to the buccal region are also disclosed.
1. A method for administering insulin to the buccal mucosa comprising spraying an effective amount of said insulin to the buccal mucosa using a metered dose inhaler, while resisting substantial inhalation of said insulin.
2. The method of claim 1 , wherein said insulin is in a mixed micelle formulation.
3. The method of claim 2 , wherein said formulation comprises: akali metal C 8 –C 22 alkyl sulfate, a pharmaceutically acceptable edetate, at least one alkali metal salicylate, and at least one micelle forming compound selected from the group consisting of lecithin, hyaluronic acid, pharmaceutically acceptable salts of hyaluronic acid, octylphenoxypolyethoxyethanol, glycolic acid, lactic acid, chamomile extract, cucumber extract, oleic acid, linolenic acid, borage oil, evening primrose oil, menthol, trihydroxy oxo cholanylglycine and pharmaceutically acceptable salts thereof, glycerin, polyglycerin, lysine, polylysine, polidocanol alkyl ethers and analogues thereof, triolein and mixtures thereof; wherein each of said sulfate, edetate and salicylate is present in a concentration of from 1 to 10 wt./wt. % of the total formulation, and wherein each micelle forming compound is present in a concentration of from 1 to 10 wt./wt. % of the total formulation, and the total concentration of sulfate, edetate, salicylate, and micelle forming compounds is less than 50 wt./wt. % of the formulation.
4. The method of claim 2 , wherein said micelles are 1 to 10 nm in size.
5. The method of claim 3 , wherein said alkali metal C 8 –C 22 sulfate is sodium lauryl sulfate.
6. The method of claim 3 , wherein said edetate is an alkali metal edetate.
7. The method of claim 3 , wherein said alkali metal salicylate is sodium salicylate.
8. The method of claim 3 , wherein said micelle forming compound is lecithin, lecithin in combination with hyaluronic acid, evening of primrose oil or borage oil.
9. The method of claim 3 , wherein said formulation comprises a combination selected from the group consisting of:
i) sodium lauryl sulfate, sodium salicylate, disodium edetate, saturated phospholipid and sodium hyaluronate;
ii) sodium lauryl sulfate, sodium salicylate, disodium edetate, lecithin and sodium hyaluronate;
iii) sodium lauryl sulfate, sodium salicylate, disodium edetate, sodium hyaluronate and evening primrose oil;
iv) sodium lauryl sulfate, sodium salicylate, disodium edetate, saturated phospholipid and bacitracin;
v) sodium lauryl sulfate, sodium salicylate, disodium edetate, saturated phospholipid, sodium hyaluronate and bacitricin; and
vi) sodium lauryl sulfate, sodium salicylate, disodium edetate, sodium hyaluronate, oleic acid and gamma linoleic acid.
10. The method of claim 3 , wherein said mixed micelle formulation further comprises water.
11. The method of claim 1 , wherein said insulin is administered in solution.